Privia Health Group (NASDAQ: PRVA - Get Free Report) and Azenta (NASDAQ: AZTA - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Risk and Volatility Privia Health Group has a
Butterfly Network (NYSE: BFLY - Get Free Report) and Privia Health Group (NASDAQ: PRVA - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends. Valuation and Earnings This table compares Butterfly
Pulmonx (NASDAQ: LUNG - Get Free Report) and Privia Health Group (NASDAQ: PRVA - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability. Analyst Ratings This is a breakdown of current
Privia Health Group (NASDAQ: PRVA - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership. Profitability This table compares
ARLINGTON, Va., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its fourth-quarter and twelve-month periods ended December 31, 2025 before market open on Thursday, February 26, 2026.
Three Healthcare IT stocks have surged over 20% in 2025, driven by growth in telehealth, remote monitoring and value-based care platforms.
Privia Health Group (NASDAQ: PRVA - Get Free Report) and Decision Diagnostics (OTCMKTS:DECN - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Volatility and Risk Privia Health Group has
Privia Health Group, Inc. (NASDAQ: PRVA - Get Free Report) CFO David Mountcastle sold 23,887 shares of the firm's stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $25.03, for a total transaction of $597,891.61. Following the completion of the sale, the chief financial officer owned
Precipio (NASDAQ: PRPO - Get Free Report) and Privia Health Group (NASDAQ: PRVA - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings. Risk and Volatility Precipio has a beta of
Capital Fund Management S.A. bought a new position in shares of Privia Health Group, Inc. (NASDAQ: PRVA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 28,510 shares of the company's stock, valued at approximately $656,000. Several
Cetera Investment Advisers lessened its stake in shares of Privia Health Group, Inc. (NASDAQ: PRVA) by 4.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 59,206 shares of the company's stock after selling 2,730 shares during the quarter. Cetera Investment Advisers'
Shares of Privia Health Group, Inc. (NASDAQ: PRVA - Get Free Report) have earned an average rating of "Moderate Buy" from the sixteen ratings firms that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The
Advantage Alpha Capital Partners LP acquired a new position in shares of Privia Health Group, Inc. (NASDAQ: PRVA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 171,357 shares of the company's stock, valued at approximately $3,941,000. Advantage Alpha Capital Partners LP owned
Privia Health Group (NASDAQ: PRVA - Get Free Report) and 111 (NASDAQ: YI - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Institutional and Insider Ownership 94.5% of Privia Health
Bailard Inc. acquired a new stake in Privia Health Group, Inc. (NASDAQ: PRVA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 23,100 shares of the company's stock, valued at approximately $531,000. Several other institutional investors have also recently
Privia Health Group, Inc. ( PRVA ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Robert Borchert - Senior Vice President of Investor Relations & Corporate Communications Parth Mehrotra - CEO & Director David Mountcastle - Executive VP, CFO & Principal Accounting Officer Conference Call Participants Marco Criscuolo - Nephron Research LLC Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Benjamin Mayo - Leerink Partners LLC, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Thomas Walsh - Barclays Bank PLC, Research Division Matthew Shea - Needham & Company, LLC, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Jeffrey Garro - Stephens Inc., Research Division Ryan Langston - TD Cowen, Research Division Albert Rice - UBS Investment Bank, Research Division Constantine Davides - Citizens JMP Securities, LLC, Research Division Derek Gross - Piper Sandler & Co., Research Division Daniel Grosslight - Citigroup Inc., Research Division Jack Slevin - Jefferies LLC, Research Division Jenny Shen - BTIG, LLC, Research Division Ryan Daniels - William Blair & Company L.L.C., Research Division Presentation Operator Hello, and welcome to the Privia Health Third Quarter 2025 Results Conference Call.
The headline numbers for Privia Health (PRVA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Privia Health (PRVA) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.
Privia Health Reports Very Strong Q3 and YTD Results Across the Business; FY'25 Guidance Raised Above High End for All Key Operating and Financial Metrics
State of New Jersey Common Pension Fund D lifted its position in shares of Privia Health Group, Inc. (NASDAQ: PRVA) by 3.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 81,534 shares of the company's stock after purchasing an additional 2,607